Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Characteristic roadmap of linker governs the rational design of PROTACs
Yawen Dong, Tingting Ma, Ting Xu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4266-4295
Open Access | Times Cited: 22

Showing 22 citing articles:

PROTAC technology: From drug development to probe technology for target deconvolution
Si Yan, Guangshuai Zhang, Wei Luo, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116725-116725
Closed Access | Times Cited: 19
Analyzing the Linker Structure of PROTACs throughout the Induction Process: Computational Insights
Yihao Li, Xiaoxuan Zhang, Jiali Xie, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 1
DNA Tetrahedron-Driven Multivalent Proteolysis-Targeting Chimeras: Enhancing Protein Degradation Efficiency and Tumor Targeting
Shiqing Li, Tao Zeng, Zhixing Wu, et al.
Journal of the American Chemical Society (2025)
Closed Access
Recent advances in interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and PROTACs
Yifan Feng, Chengjuan Chen, Anqi Shao, et al.
Chinese Chemical Letters (2025), pp. 110963-110963
Closed Access
In silico modeling of targeted protein degradation
Wenxing Lv, Xiaojuan Jia, Bowen Tang, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117432-117432
Open Access
Computational approaches to aid PROTAC drug discovery
Sohini Chakraborti, Kirsten McAulay
Elsevier eBooks (2025)
Closed Access
Application of DELs for E3 Ligase Ligand Discovery and Targeted Protein Degradation
Marie L. Malone, Nicholas A. Sanchez, Shimin Hu, et al.
Royal Society of Chemistry eBooks (2025), pp. 134-156
Closed Access
Rational Proteolysis Targeting Chimera Design Driven by Molecular Modeling and Machine Learning
Shuoyan Tan, Zhuo Chen, Ruiqiang Lu, et al.
Wiley Interdisciplinary Reviews Computational Molecular Science (2025) Vol. 15, Iss. 2
Closed Access
Strategies for Precise Modulation of Protein Degradation
Shipeng He, Guoqiang Dong, Chunquan Sheng
Accounts of Chemical Research (2025)
Closed Access
Computational methods and key considerations for in silico design of proteolysis targeting chimera (PROTACs)
Amr E. Abbas, Fei Ye
International Journal of Biological Macromolecules (2024) Vol. 277, pp. 134293-134293
Closed Access | Times Cited: 3
Design and optimization strategies of PROTACs and its Application, Comparisons to other targeted protein degradation for multiple oncology therapies
M. Malarvannan, S. Unnikrishnan, S. Monohar, et al.
Bioorganic Chemistry (2024) Vol. 154, pp. 107984-107984
Closed Access | Times Cited: 3
Targeting Oncogenic Transcriptional Factor c-Myc by Oligonucleotide PROTAC for the Treatment of Hepatocellular Carcinoma
Min Ai, Hulin Ma, Jianhua He, et al.
European Journal of Medicinal Chemistry (2024) Vol. 280, pp. 116978-116978
Closed Access | Times Cited: 2
To homeostasis and beyond! Recent advances in the medicinal chemistry of heterobifunctional derivatives
Diana Castagna, Benoit Gourdet, Roland Hjerpe, et al.
Progress in medicinal chemistry (2024), pp. 61-160
Closed Access | Times Cited: 1
ET-PROTACs: modeling ternary complex interactions using cross-modal learning and ternary attention for accurate PROTAC-induced degradation prediction
Lijun Cai, Guanghui Yue, Yifan Chen, et al.
Briefings in Bioinformatics (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 1
Discovery of an efficacious KDM5B PROTAC degrader GT-653 up-regulating IFN response genes in prostate cancer
Tian Guan, Yingshuang Zhang, Li Shen, et al.
European Journal of Medicinal Chemistry (2024) Vol. 272, pp. 116494-116494
Closed Access | Times Cited: 1
FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives
Heba M. Hesham, Eman M.E. Dokla, Eman Z. Elrazaz, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116717-116717
Closed Access | Times Cited: 1
Non-Markovian Dynamic Models Identify Non-Canonical KRAS-VHL Encounter Complex Conformations for Novel PROTAC Design
Yunrui Qiu, Rafal Wiewiora, Jesús A. Izaguirre, et al.
JACS Au (2024) Vol. 4, Iss. 10, pp. 3857-3868
Open Access | Times Cited: 1
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)
Xiang Fei
Expert Opinion on Therapeutic Patents (2024)
Closed Access | Times Cited: 1
CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications
Riya Thapa, Asif Ahmad Bhat, Gaurav Gupta, et al.
Chemical Biology & Drug Design (2024) Vol. 104, Iss. 5
Open Access | Times Cited: 1
Erythroid progenitor cell modulates cancer immunity: Insights and implications
Wentao Mo, Cong‐Fa Huang, Zhi‐Jun Sun
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 6, pp. 189209-189209
Closed Access | Times Cited: 1
Chemical Dissection of Selective Myeloid Leukemia-1 Inhibitors: How They Were Found and Evolved
Lianzhou Wang, Yuxiang Chen, MeiZhi Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 283, pp. 117168-117168
Closed Access | Times Cited: 1
Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions
Akash Vikal, Rashmi Maurya, Brij Bihari Patel, et al.
Drug Delivery and Translational Research (2024)
Closed Access
Page 1

Scroll to top